PCI treats the blockage. But does it fully treat the biology behind recurrent coronary events?
Our new review explores the next frontier of coronary care: targeted molecular therapies beyond stents!
https://t.co/0pKIme7Wmq
@dimuro_fra@MarcoBernardiMD@arturocesaro
Because of their distinctive anatomy, bicuspid aortic valves carry a higher risk of suboptimal procedural results and complications during TAVI. This review provides an updated synthesis of current evidence on TAVI in bicuspid aortic stenosis and outlines potential future developments in the field. https://t.co/RO6FTtu9YV
Presented at #AHA25:
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: https://t.co/1LiJFFvnm3
@AHAScience
The PROTECT IV trial is a prospective, multicenter, randomized study evaluating whether routine Impella CP support during high-risk PCI improves outcomes in patients with complex CAD and LVEF ≤40% (n=1,252) deemed unsuitable for surgery. Patients are randomized 1:1 to PCI with Impella CP versus PCI with or without IABP. The primary endpoint is a composite of death, stroke, MI, revascularization, advanced heart failure therapy, or cardiovascular hospitalization at 3 years. https://t.co/x3Khemg00s
A 70 yo man w/ h/o HTN, HLD, T2DM, HFpEF and AF presented for sudden onset shortness of breath. What pattern does the ECG show? What is the most appropriate next intervention? https://t.co/0F195TfMWU #AHAJournals